{
    "organizations": [],
    "uuid": "049bc4d00309bc8e9a2594f687594991a0656f0a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biotest-new-data-from-monoclonal-a/brief-biotest-new-data-from-monoclonal-antibody-drug-conjugate-bt-062-idUSFWN1SA034",
    "ord_in_thread": 0,
    "title": "Biotest: New Data From Monoclonal Antibody-Drug-Conjugate BT-062",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 3 (Reuters) - Biotest AG:\n* DGAP-NEWS: BIOTEST AG: NEW DATA FROM BIOTESTâ€™S MONOCLONAL ANTIBODY-DRUG-CONJUGATE (ADC) BT-062 IN THE THERAPY OF SOLID TUMORS\n* GOOD TOLERABILITY AND SIGNS OF EFFICACY IN PHASE I/IIA CLINICAL STUDY\n* VERY GOOD EFFECTIVENESS WHEN COMBINED WITH CHEMOTHERAPEUTIC AGENT IN PRECLINICAL STUDIES ON DIFFICULT TO TREAT BREAST CANCER\n* BIOTEST IS SEEKING INVESTORS FOR FURTHER DEVELOPMENT OF BT-062 Source text for Eikon: (Gdynia Newsroom)\nOur ",
    "published": "2018-05-03T13:09:00.000+03:00",
    "crawled": "2018-05-04T16:47:02.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "biotest",
        "ag",
        "biotest",
        "ag",
        "new",
        "data",
        "biotest",
        "monoclonal",
        "adc",
        "therapy",
        "solid",
        "tumor",
        "good",
        "tolerability",
        "sign",
        "efficacy",
        "phase",
        "clinical",
        "study",
        "good",
        "effectiveness",
        "combined",
        "chemotherapeutic",
        "agent",
        "preclinical",
        "study",
        "difficult",
        "treat",
        "breast",
        "cancer",
        "biotest",
        "seeking",
        "investor",
        "development",
        "source",
        "text",
        "eikon",
        "gdynia",
        "newsroom"
    ]
}